Arcellx Inc.
Gilead to Acquire Arcellx in $7.8 Billion Deal to Accelerate Anito-cel Development
Summary
Arcellx, Inc. has entered into a definitive agreement to be acquired by Gilead Sciences, Inc. for $115 per share in cash and one contingent value right of $5 per share, representing an implied equity value of $7.8 billion. The acquisition aims to accelerate the development and commercialization of Arcellx's lead product candidate, anitocabtagene autoleucel (anito-cel), a BCMA-directed CAR T-cell therapy for patients with multiple myeloma. Gilead, which already owns approximately 11.5% of Arcellx's outstanding common stock, will commence a tender offer to acquire all remaining shares through a two-step transaction. The acquisition is expected to be accretive to Gilead's earnings per share in 2028 and thereafter, following FDA approval of anito-cel.
Profitelligence Alerts
Get alerts for ACLX
Be first to know when Arcellx Inc. files with the SEC.
Filing Categories
Advertisement
About Arcellx Inc.
Arcellx Inc. is a biopharmaceutical company specializing in the development of innovative cell therapies for the treatment of cancer and other debilitating diseases. The company's primary goal is to harness the power of the immune system through its proprietary D-Domain technology platform, which is designed to improve the efficacy and safety of cell-based treatments. Arcellx focuses on targeting malignant cells with precision, thereby enhancing therapeutic outcomes and minimizing adverse effects. Operating within the highly complex and rapidly evolving biotechnology sector, Arcellx significantly contributes to advancements in life sciences and medical treatments. Given its commitment to pioneering scientific discoveries, the company represents a significant player in the push towards personalized medicine and novel cancer therapies. Through collaboration with academic institutions and strategic partnerships, Arcellx endeavors to accelerate the development and commercialization of its pipeline products, aiming to bring life-changing treatments to patients worldwide. Its research-intensive approach and focus on addressing unmet medical needs position Arcellx as an impactful entity in the biopharmaceutical landscape.
Official SEC Documents
Advertisement